Therefore, we conducted the first randomized phase II trial to evaluate the efficacy and safety of triple HER2 blockade with trastuzumab, pertuzumab, and pyrotinib (TPPy) versus dual TP therapy in the neoadjuvant treatment of patients with HER2‐positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.